ic980410c_si_001.pdf (1009.1 kB)
Stepwise Cluster Assembly Using VO2(acac) as a Precursor: cis-[VO(OCH(CH3)2)(acac)2], [V2O2(μ-OCH3)2(acac)2(OCH3)2], [V3O3{μ,μ-(OCH2)3CCH3}2(acac)2(OC2H5)], and [V4O4(μ-O)2(μ-OCH3)2(μ3-OCH3)2(acac)2(OCH3)2]·2CH3CN1
journal contribution
posted on 1998-09-24, 00:00 authored by Feilong Jiang, Oren P. Anderson, Susie M. Miller, John Chen, Mohammad Mahroof-Tahir, Debbie C. CransThe studies of an underexplored synthetic reagent, VO2(acac) (Hacac = acetylacetone) and semirational strategies
for the formation of a complete series of simple vanadium(V) alkoxide clusters in alcohol-containing solvents.
The neutral mono-, di-, tri-, and tetranuclear oxovanadium(V) complexes [V2O2(μ-OCH3)2(acac)2(OCH3)2] (1),
[V4O4(μ-O)2(μ-OCH3)2(μ3-OCH3)2(acac)2(OCH3)2]·2CH3CN (2), [V4O4(μ-O)2(μ-OCH3)2(μ3-OCH3)2(acac)2(OCH3)2] (3), [V3O3{μ,μ-(OCH2)3CCH3}2(acac)2(OR)] (R = CH3 (4), C2H5 (5)), and cis-[VO(OCH(CH3)2)(acac)2]
(6) with alkoxide and acac- ligands were obtained by reaction of VO2(acac) with a monoalcohol and/or a tridentate
alcohol. The structures of complexes 1−3, 5, and 6 were determined by X-ray diffraction methods. Complex 1
crystallized in the monoclinic system, P21/n, with a = 7.8668(5) Å, b = 15.1037(9) Å, c = 8.5879(5) Å, β =
106.150(1)°, V = 980.1(1) Å3, Z = 2, and R (wR2) = 0.040 (0.121). Complex 2 crystallized in the monoclinic
system, P21/n, with a = 8.531(2) Å, b = 14.703(3) Å, c = 12.574(2) Å, β = 95.95(2)°, V = 1568.7(5) Å3, Z =
2, and R (wR2) = 0.052 (0.127). Complex 3 crystallized in the triclinic system, P1̄, with a = 8.5100(8) Å, b =
8.9714(8) Å, c = 10.3708(10) Å, α = 110.761(1)°, β = 103.104(1)°, γ = 100.155(1)°, V = 691.85(11) Å3, Z =
1, and R (wR2) = 0.040 (0.105). Complex 5 crystallized in the monoclinic system, P21/n, with a = 14.019(2)
Å, b = 11.171(2) Å, c = 19.447(3) Å, β = 109.18(1)°, V = 2876.5(8) Å3, Z = 4, and R (wR2) = 0.062 (0.157).
Complex 6 crystallized in the monoclinic system, P21/n, with a = 15.0023(8) Å, b = 8.1368(1) Å, c = 26.5598(2) Å, β = 95.744(1)°, V = 3225.89(8) Å3, Z = 8, and R (wR2) = 0.060 (0.154). Complex 1 is a discrete,
centrosymmetric dimer in which two vanadium atoms are bridged by two methoxide ligands. Compound 2 contains
a V4O4 eight-membered ring with both μ-oxo and μ-alkoxo bridging ligands; the ring is capped above and below
by two triply bridging methoxo ligands. Compound 3 has the same structure as 2. The three vanadium atoms
in complex 5 are linked by four bridging oxygen atoms from two tridentate thme3- ligands to form a V3O4 chain
in which V−O bonds alternate in length. The V−O(isopropoxo) bond in 6 is cis to VO, and the V−O(acac)
bond trans to the oxo group is relatively long. The V2O2 rings of complex 1 and the mononuclear 1:2 complex
can be considered to be the basic building block of the trinuclear complexes 4 and 5 and the tetranuclear complex
2, acting to extend the vanadium−oxide framework. 51V and 1H NMR spectroscopic studies of the solution state
of complexes 1−6 revealed dramatic differences in structural and hydrolytic stability of these complexes.
Compounds 1 and 3 only remained intact at low temperature in CDCl3 solution, whereas the mononuclear compound
6 could remain at ambient temperature for ∼10 h. Compound 4 only maintained its solid-state structure at low
temperature in CDCl3 solution, whereas compound 5 was significantly more stable. The structural integrity of
oligomeric vanadium−oxygen frameworks increased significantly when the coordinating alkoxide group showed
more resistance to exchange reactions than the methoxide group. The solid state and solution properties of this
new group of complexes not only testify to the versatility of VO2(acac) as a vanadium(V) precursor but also raise
questions relating to solution structure and properties of related vanadium complexes with insulin-mimetic properties
and catalytic properties.
